Published Issues

Effect of Vitamin D Adjuvant and Allergen Specific Immunotherapy on Serum IL-10 and IL-17 Levels in Childhood Asthma: A Controlled Clinical Trial

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive

1Lobna A. El-Korashi*, Ola E. Nafea2, Lamiaa G. Zake3, Faika Arab4, 1Reham H. Anis

1Department of Medical Microbiology and Immunology, Faculty of Medicine, Zagazig University, Egypt

2Department of Clinical Toxicology and Forensic Medicine, Faculty of Medicine, Zagazig University, Egypt

3Chest Department, Faculty of Medicine, Zagazig University, Egypt

4Paediatric Department, Faculty of Medicine, Zagazig University, Egypt



Background: 1, 25-dihydroxy vitamin D3 (VitD3) can improve the effect of allergen-specific immunotherapy (SIT). Few data is available about its role in childhood asthma. Objective: To assess the immunological and clinical efficacy of VitD3 as an adjuvant to allergen specific immunotherapy in pediatric asthma. Methodology: Sixty nine children with atopic asthma were divided into three groups: a group received subcutaneous immunotherapy (SCIT) in combination with VitD3 (n=23), another group received SCIT alone (n=23), and the last group VitD3 alone (n=23). All children were assessed at baseline, and six months for rate of inhaled corticosteroid (ICS) discontinuation, and serum levels of IL-10, and IL-17A. Results: In the SCIT + vitD3, ICS discontinuation rate was higher compared to VitD3 alone group and SCIT alone group at the end of 6th month (P=0.555 and 0.016 respectively).  The combined SCIT+ VitD3 group showed significant increase of serum IL-10 level in comparison to SCIT alone group and VitD3 alone group (P=0.000) and significant decrease in serum IL-17A level compared to VitD3 alone group (P= 0.011) Conclusion: VitD3 enhance the clinical and immunological outcomes of SIT in pediatric asthma. Further investigation is needed to evaluate this effect in a larger scale to confirm its role as an adjunct to SIT.

© All Rights Reserved. Designed By